Found: 48
Select item for more details and to access through your institution.
Further Evidence That OPG rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast Cancer.
- Published in:
- Frontiers in Genetics, 2021, v. 11, p. 1, doi. 10.3389/fgene.2021.662734
- By:
- Publication type:
- Article
Co-occurrence and metabolic biomarkers of sensory and motor subtypes of peripheral neuropathy from paclitaxel.
- Published in:
- Breast Cancer Research & Treatment, 2022, v. 194, n. 3, p. 551, doi. 10.1007/s10549-022-06652-x
- By:
- Publication type:
- Article
Vitamin D deficiency increases severity of paclitaxel-induced peripheral neuropathy.
- Published in:
- Breast Cancer Research & Treatment, 2020, v. 180, n. 3, p. 707, doi. 10.1007/s10549-020-05584-8
- By:
- Publication type:
- Article
Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion.
- Published in:
- Breast Cancer Research & Treatment, 2019, v. 175, n. 2, p. 297, doi. 10.1007/s10549-019-05158-3
- By:
- Publication type:
- Article
Pharmacometabolomics reveals a role for histidine, phenylalanine, and threonine in the development of paclitaxel-induced peripheral neuropathy.
- Published in:
- Breast Cancer Research & Treatment, 2018, v. 171, n. 3, p. 657, doi. 10.1007/s10549-018-4862-3
- By:
- Publication type:
- Article
Strategies for DPYD testing prior to fluoropyrimidine chemotherapy in the US.
- Published in:
- Supportive Care in Cancer, 2024, v. 32, n. 8, p. 1, doi. 10.1007/s00520-024-08674-1
- By:
- Publication type:
- Article
Patient perceptions of altering chemotherapy treatment due to peripheral neuropathy.
- Published in:
- Supportive Care in Cancer, 2024, v. 32, n. 1, p. 1, doi. 10.1007/s00520-023-08209-0
- By:
- Publication type:
- Article
Evolution of predictive risk factor analysis for chemotherapy-related toxicity.
- Published in:
- Supportive Care in Cancer, 2023, v. 31, n. 10, p. 1, doi. 10.1007/s00520-023-08074-x
- By:
- Publication type:
- Article
Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptoms.
- Published in:
- Supportive Care in Cancer, 2022, v. 30, n. 10, p. 8059, doi. 10.1007/s00520-022-07243-8
- By:
- Publication type:
- Article
Lack of association of CYP2B6 pharmacogenetics with cyclophosphamide toxicity in patients with cancer.
- Published in:
- Supportive Care in Cancer, 2022, v. 30, n. 9, p. 7355, doi. 10.1007/s00520-022-07118-y
- By:
- Publication type:
- Article
Neuropathy severity at the time of oxaliplatin treatment alteration in patients with colon cancer (Alliance A151912).
- Published in:
- Supportive Care in Cancer, 2021, v. 29, n. 12, p. 7855, doi. 10.1007/s00520-021-06371-x
- By:
- Publication type:
- Article
Reporting of paclitaxel-induced peripheral neuropathy symptoms to clinicians among women with breast cancer: a qualitative study.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Incorporation of emergent symptoms and genetic covariates improves prediction of aromatase inhibitor therapy discontinuation.
- Published in:
- JAMIA Open, 2024, v. 7, n. 1, p. 1, doi. 10.1093/jamiaopen/ooae006
- By:
- Publication type:
- Article
Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity.
- Published in:
- Journal of Human Genetics, 2013, v. 58, n. 6, p. 346, doi. 10.1038/jhg.2013.42
- By:
- Publication type:
- Article
Comparison of eight screening tools to detect interactions between herbal supplements and oncology agents.
- Published in:
- Journal of Oncology Pharmacy Practice, 2020, v. 26, n. 8, p. 1843, doi. 10.1177/1078155220905009
- By:
- Publication type:
- Article
Drug interaction screening in SWOG clinical trials.
- Published in:
- American Journal of Health-System Pharmacy, 2018, v. 75, n. 10, p. 607, doi. 10.2146/ajhp170449
- By:
- Publication type:
- Article
Pre-treatment amino acids and risk of paclitaxel-induced peripheral neuropathy in SWOG S0221.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2024, v. 94, n. 2, p. 311, doi. 10.1007/s00280-024-04680-6
- By:
- Publication type:
- Article
Using maximum plasma concentration (C<sub>max</sub>) to personalize taxane treatment and reduce toxicity.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2024, v. 93, n. 6, p. 525, doi. 10.1007/s00280-024-04677-1
- By:
- Publication type:
- Article
Muscle mass affects paclitaxel systemic exposure and may inform personalized paclitaxel dosing.
- Published in:
- British Journal of Clinical Pharmacology, 2022, v. 88, n. 7, p. 3222, doi. 10.1111/bcp.15244
- By:
- Publication type:
- Article
Genetic variation in EPHA contributes to sensitivity to paclitaxel‐induced peripheral neuropathy.
- Published in:
- British Journal of Clinical Pharmacology, 2020, v. 86, n. 5, p. 880, doi. 10.1111/bcp.14192
- By:
- Publication type:
- Article
Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226.
- Published in:
- British Journal of Clinical Pharmacology, 2016, v. 81, n. 6, p. 1134, doi. 10.1111/bcp.12904
- By:
- Publication type:
- Article
In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles.
- Published in:
- British Journal of Clinical Pharmacology, 2015, v. 80, n. 5, p. 1122, doi. 10.1111/bcp.12665
- By:
- Publication type:
- Article
Pilot study of rosiglitazone as an in vivo probe of paclitaxel exposure.
- Published in:
- British Journal of Clinical Pharmacology, 2012, v. 74, n. 1, p. 197, doi. 10.1111/j.1365-2125.2012.04165.x
- By:
- Publication type:
- Article
UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation.
- Published in:
- Cancers, 2021, v. 13, n. 7, p. 1566, doi. 10.3390/cancers13071566
- By:
- Publication type:
- Article
Potential Utility of Pre-Emptive Germline Pharmacogenetics in Breast Cancer.
- Published in:
- Cancers, 2021, v. 13, n. 6, p. 1219, doi. 10.3390/cancers13061219
- By:
- Publication type:
- Article
Genetic Predictors of Chemotherapy-Induced Peripheral Neuropathy from Paclitaxel, Carboplatin and Oxaliplatin: NCCTG/Alliance N08C1, N08CA and N08CB Study.
- Published in:
- Cancers, 2021, v. 13, n. 5, p. 1084, doi. 10.3390/cancers13051084
- By:
- Publication type:
- Article
Clinical CYP2D6 Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy.
- Published in:
- Cancers, 2021, v. 13, n. 4, p. 771, doi. 10.3390/cancers13040771
- By:
- Publication type:
- Article
Genetic Variations and Health-Related Quality of Life (HRQOL): A Genome-Wide Study Approach.
- Published in:
- Cancers, 2021, v. 13, n. 4, p. 716, doi. 10.3390/cancers13040716
- By:
- Publication type:
- Article
Recommendations for pharmacogenetic testing in clinical practice guidelines in the US.
- Published in:
- American Journal of Health-System Pharmacy, 2024, v. 81, n. 16, p. 672, doi. 10.1093/ajhp/zxae110
- By:
- Publication type:
- Article
Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity.
- Published in:
- American Journal of Epidemiology, 2017, v. 185, n. 2, p. 75, doi. 10.1093/aje/kww178
- By:
- Publication type:
- Article
Drug-drug interactions in subjects enrolled in SWOG trials of oral chemotherapy.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Risk of Toxicity From Topical 5‐Fluorouracil Treatment in Patients Carrying DPYD Variant Alleles.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 3, p. 452, doi. 10.1002/cpt.3131
- By:
- Publication type:
- Article
Response to the FDA Decision Regarding DPYD Testing Prior to Fluoropyrimidine Chemotherapy.
- Published in:
- Clinical Pharmacology & Therapeutics, 2023, v. 114, n. 4, p. 768, doi. 10.1002/cpt.2978
- By:
- Publication type:
- Article
Confirmatory DPYD Testing in Patients Receiving Fluoropyrimidines Who are Suspected DPYD Variant Carriers Based on a Genetic Data Repository.
- Published in:
- Clinical Pharmacology & Therapeutics, 2023, v. 114, n. 2, p. 356, doi. 10.1002/cpt.2936
- By:
- Publication type:
- Article
Analysis Approaches to Identify Pharmacogenetic Associations With Pharmacodynamics.
- Published in:
- Clinical Pharmacology & Therapeutics, 2021, v. 110, n. 3, p. 589, doi. 10.1002/cpt.2312
- By:
- Publication type:
- Article
Planning and Conducting a Pharmacogenetics Association Study.
- Published in:
- Clinical Pharmacology & Therapeutics, 2021, v. 110, n. 3, p. 688, doi. 10.1002/cpt.2270
- By:
- Publication type:
- Article
Prevalence of drug-drug interactions in oncology patients enrolled on National Clinical Trials Network oncology clinical trials.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Feasibility of pharmacometabolomics to identify potential predictors of paclitaxel pharmacokinetic variability.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Correction: Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients.
- Published in:
- 2022
- By:
- Publication type:
- corrected article
Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group.
- Published in:
- CTS: Clinical & Translational Science, 2020, v. 13, n. 1, p. 116, doi. 10.1111/cts.12692
- By:
- Publication type:
- Article
Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance).
- Published in:
- Cancer (0008543X), 2015, v. 121, n. 7, p. 1025, doi. 10.1002/cncr.29169
- By:
- Publication type:
- Article
Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity.
- Published in:
- Oncologist, 2016, v. 21, n. 7, p. 795, doi. 10.1634/theoncologist.2015-0480
- By:
- Publication type:
- Article
Tamoxifen and CYP2D6: A Contradiction of Data.
- Published in:
- Oncologist, 2012, v. 17, n. 5, p. 620, doi. 10.1634/theoncologist.2011-0418
- By:
- Publication type:
- Article
Osteonecrosis of the jaw risk factors in bisphosphonate‐treated patients with metastatic cancer.
- Published in:
- Oral Diseases, 2022, v. 28, n. 1, p. 193, doi. 10.1111/odi.13746
- By:
- Publication type:
- Article
Wearables, sensors, and smart devices for the detection and monitoring of chemotherapy‐induced peripheral neurotoxicity: Systematic review and directions for future research.
- Published in:
- Journal of the Peripheral Nervous System, 2022, v. 27, n. 4, p. 238, doi. 10.1111/jns.12518
- By:
- Publication type:
- Article
Genotyping concordance in DNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analyses.
- Published in:
- Molecular Oncology, 2015, v. 9, n. 9, p. 1868, doi. 10.1016/j.molonc.2015.07.002
- By:
- Publication type:
- Article